published meta-analysis   sensitivity analysis   studies

antiviral and associated therapy in COVID 19 all comers - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death or transfer to ICUdetailed resultsjRCTs041190120, 2020 1.02 [0.02; 52.72] 1.02[0.02; 52.72]jRCTs041190120, 202010%89NAnot evaluable viral clearance detailed resultsjRCTs041190120, 2020 1.42 [0.76; 2.62] 1.42[0.76; 2.62]jRCTs041190120, 202010%89NAnot evaluable viral clearance (time to event analysis only)detailed resultsjRCTs041190120, 2020 1.42 [0.76; 2.62] 1.42[0.76; 2.62]jRCTs041190120, 202010%89NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-06-18 01:06 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 94 - treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814 - roots T: 290